Alcon Inc. Reports Strong Second‑Quarter Growth and Raises Full‑Year Guidance

Alcon Inc. (ALC), the Swiss‑listed eye‑care specialist, announced its second‑quarter 2026 results on August 10, 2026. Net sales rose 8 % to US$2.78 billion, or 7 % on a constant‑currency basis, driven by continued demand for its vitreoretinal and cataract surgery products, contact lenses, and refractive technology.

Gross margin improved markedly to 60.2 % from 53.9 % in the same period a year earlier, reflecting disciplined cost management and a favorable product mix. Core net income for the quarter reached US$410 million, or US$0.84 per share, versus US$372 million (US$0.76 per share) a year earlier. Net income attributable to shareholders was zero, down from US$176 million (US$0.35 per share) in Q2 2025, primarily due to higher operating costs and a one‑time charge related to restructuring.

Guidance Update

Alcon has raised its 2026 core operating‑margin and core diluted EPS growth targets. The company now expects core operating margin growth of 12 %–15 % and core diluted EPS growth of 12 %–15 %, a revision up from the previous outlook of 5 %–10 %. The upward revision follows an improved earnings outlook and a reduction in tariff exposure.

Alcon now anticipates that tariff impacts for 2026 will be between US$40 million and US$90 million, compared with the prior estimate of US$100 million to US$150 million. The company attributes this adjustment to an expected US$60 million refund from the U.S. government and a broader easing of tariff concerns.

Market Reaction

The revised outlook and tariff revision prompted a 3 % rally in Alcon’s stock on the SIX Swiss Exchange. Analysts noted that the earnings upgrade, combined with the lower tariff forecast, reinforced investor confidence in the company’s profitability trajectory.

Dividend and Share‑Repurchase Activity

Alcon returned US$538 million to shareholders during the year to date through dividends and share repurchases, underscoring its commitment to creating shareholder value while maintaining investment in growth initiatives.

Summary

Alcon Inc.’s second‑quarter performance, characterized by solid revenue growth, margin expansion, and a significant revision of full‑year guidance, reflects the company’s resilience in a competitive health‑care equipment market. The reduction in tariff exposure and the upward revision of core earnings targets are expected to support continued investor interest and a positive market outlook for the remainder of 2026.